In Autumn 2015 BMC supported Helix Polska in grant application for 1/1.1.1/2015 (“Fast track”) program by The National Centre for Research and Development, for the project “Development of a new, effective and highly specific therapy for breast cancer, with low toxicity profile, based on patented DOS47 technology platform, modifying tumor’s microenvironment and antitumor immune response throughout the pH alteration”.
The project included substantive preparation of the grant application parts, concerning:
– market (target market characteristics, demand for project results analysis , competitive environment)
– project results novelty
– project’s commercialization strategy and its profitability (risk analysis, intellectual property environment analysis, preliminary valuation of the project).